Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 8—August 2013
Research

Accuracy of Diagnostic Methods and Surveillance Sensitivity for Human Enterovirus, South Korea, 1999–2011

Ji-Yeon Hyeon, Seoyeon Hwang, Hyejin Kim, Jaehyoung Song, Jeongbae Ahn, Byunghak Kang, Kisoon Kim, Wooyoung Choi, Jae Keun Chung, Cheon-Hyun Kim, Kyungsoon Cho, Youngmee Jee, Jonghyun Kim, Kisang Kim, Sun-Hee Kim, Min-Ji Kim, and Doo-Sung CheonComments to Author 
Author affiliations: Korea Center for Disease Control and Prevention, Cheongwon-gun, Chungcheongbuk-do, South Korea (J.-Y. Hyeon, S. Hwang, H. Kim, J. Song, J. Ahn, B. Kang, Kisoon Kim, W. Choi, Kisang Kim, D.-S. Cheon); Public Health and Environment Institute of Gwangju, Gwangju, South Korea (J.K. Chung, S.-H. Kim, M.-J. Kim); Public Health and Environment Institute of Jeollabukdo, Imsil-gun, Jeollabukdo, South Korea (C.-H. Kim); Public Health and Environment Institute of Busan, Busan, South Korea (K. Cho); World Health Organization, Western Pacific Region, Manila, Philippines (Y. Jee); Catholic University College of Medicine, Suwon, Kyeonggido, South Korea (J. Kim)

Main Article

Table 3

Five most frequent human enterovirus genotype rankings during the epidemic seasons in South Korea, by year, 1999–2011*

Year Genotype, no. (%)
Rank 1 Rank 2 Rank 3 Rank 4 Rank 5
Phase 1†





1999, n = 85 CB2, 21 (24.7) E6, 15 (17.7) CB3, 10 (11.7) E11, 8 (9.4) E30, (8 (9.4)
2000, n = 30 EV71, 12 (40) Polio Sabin strain, 9 (30) CB2, 2 (2.7) E6, 2 (2.7) E11, 2 (2.7)
2001, n = 26 CB5, 12 (46.2) CB3, 4 (15.4) Polio Sabin strain, 3 (11.6) CB2, 3 (11.6) CB1, 3 (11.6)
2002, n = 272 E13, 70 (25.7) E9, 59 (21.7) E6, 53 (19.5) E7, 24 (8.8) CB3, 17 (6.3)
2003, n = 54 CB4, 16 (19.5) E6, 10 (12.2) E30, 7 (8.5) CB1, 7 (8.5) Polio Sabin strain, 5 (6.1)
2004, n = 29 Polio Sabin strain, 7 (24.1) E30, 6 (20.7) CB2, 5 (17.3) CB1, 4 (13.8) E6, 3 (10.3)
Phase 2‡
2005, n = 369 CB5, 159 (43.1) E18, 127 (34.4) CB3, 47 (12.7) E9, 25 (6.8) CB1, 7 (1.9)
2006, n = 238 E25, 56 (23.5) E30, 48 (20.2) E5, 28 (11.8) CA16, 20 (8.4) CB4, 18 (7.6)
2007, n = 180 CB2, 62 (34.4) CA9, 28 (15.6) EV71, 21 (11.7) E16, 14 (7.8) CA10, 10 (5.6)
Phase 3§
2008, n = 626 E30, 299 (47.8) E6, 170 (27.2) CA10, 33 (5.3) CB3, 29 (4.6) CB1, 27 (4.5)
2009, n = 288 EV71, 127 (44.1) CB1, 70 (24.3) CA2, 23 (8.0) CA5, 20 (6.9) CA14, 17 (5.9)
2010, n = 402 EV71, 190 (47.3) CA6, 65 (16.2) CB5, 32 (8.0) CA9, 28 (7.0) CA10, 19 (4.7)
2011, n = 529 EV71, 118 (22.3) CA16, 109 (20.6) CB5, 72 (13.6) CB2, 70 (13.2) E18, 42 (7.9)
Total, 1999–2011, 
n = 3,128 EV71, 476 (14.9) E30, 390 (12.5) CB5, 290 (9.3) E6, 261 (8.4) CB2, 186 (6.0)

*CB, coxsackievirus B; E, echovirus; EV, enterovirus; CA, coxsackievirus A.

Main Article

Page created: July 19, 2013
Page updated: July 19, 2013
Page reviewed: July 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external